Novartis Ag (NVSEF) Invested Capital (2009 - 2025)

Novartis Ag has disclosed Invested Capital across 12 years of filings, most recently posting $46.4 billion for Q4 2025.

• Invested Capital for Q4 2025 came in at $46.4 billion, up 3.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.3 billion (up 10.38% YoY), and the FY2025 annual result was $46.4 billion, up 3.99% from the prior year.
• Invested Capital came in at $46.4 billion for Q4 2025 at Novartis Ag, up from $8.3 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $90.7 billion in Q4 2022 to a low of $7.0 billion in Q2 2022.
• The 5-year median for Invested Capital is $26.9 billion (2021), against an average of $33.9 billion.
• Across the five-year window, Invested Capital surged 10355.86% in 2021 and sank 47.76% in 2023, its largest moves.
• Novartis Ag's Invested Capital stood at $69.6 billion in 2021, then surged by 30.23% to $90.7 billion in 2022, then tumbled by 47.76% to $47.4 billion in 2023, then retreated by 5.75% to $44.6 billion in 2024, then increased by 3.99% to $46.4 billion in 2025.
• The last three Invested Capital figures came in at $46.4 billion (Q4 2025), $8.3 billion (Q2 2025), and $44.6 billion (Q4 2024), per Business Quant data.